ADC Therapeutics SA (NYSE:ADCT) — Market Cap & Net Worth
Market Cap & Net Worth: ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (NYSE:ADCT) has a market capitalization of $474.45 Million ($474.45 Million) as of May 2, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #12794 globally and #2982 in its home market, demonstrating a -3.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ADC Therapeutics SA's stock price $3.83 by its total outstanding shares 123877111 (123.88 Million). Analyse ADCT cash generation efficiency to see how efficiently the company converts income to cash.
ADC Therapeutics SA Market Cap History: 2020 to 2026
ADC Therapeutics SA's market capitalization history from 2020 to 2026. Data shows change from $3.97 Billion to $474.45 Million (-29.05% CAGR).
ADC Therapeutics SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ADC Therapeutics SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.48x
ADC Therapeutics SA's market cap is 3.48 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.50 Billion | $33.92 Million | -$230.03 Million | 73.78x | N/A |
| 2022 | $475.69 Million | $209.91 Million | -$157.13 Million | 2.27x | N/A |
| 2023 | $205.64 Million | $69.56 Million | -$240.05 Million | 2.96x | N/A |
| 2024 | $246.52 Million | $70.84 Million | -$157.85 Million | 3.48x | N/A |
Competitor Companies of ADCT by Market Capitalization
Companies near ADC Therapeutics SA in the global market cap rankings as of May 2, 2026.
Key companies related to ADC Therapeutics SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ADC Therapeutics SA Historical Marketcap From 2020 to 2026
Between 2020 and today, ADC Therapeutics SA's market cap moved from $3.97 Billion to $ 474.45 Million, with a yearly change of -29.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $474.45 Million | +8.50% |
| 2025 | $437.29 Million | +77.39% |
| 2024 | $246.52 Million | +19.88% |
| 2023 | $205.64 Million | -56.77% |
| 2022 | $475.69 Million | -80.99% |
| 2021 | $2.50 Billion | -36.89% |
| 2020 | $3.97 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of ADC Therapeutics SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $474.45 Million USD |
| MoneyControl | $474.45 Million USD |
| MarketWatch | $474.45 Million USD |
| marketcap.company | $474.45 Million USD |
| Reuters | $474.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the Chi… Read more